Untitled design

sisupharma

Pharmaceutical company

CONTACT US
  • Home
  • Science
  • News
CONTACT US

Home » Archives for Sisu Pharma

All posts by : Sisu Pharma

Jung_Michael
April 20, 2023
by Sisu Pharma News Release

Sisu Pharma Welcomes Renowned Prostate Cancer Drug Developer Professor Michael Jung to its Scientific Advisory Board

Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board.

Read More
indoors, studio shot, digitally manipulated, layer, overlay, illustration, drawing, graphic, science, research, technology, anatomy, biology, medicine, medical, health, healthcare, micrograph, cell, cancer, disease, illness, tumor, metastases, immune system, colour, purple, black,Medical Illustrations
November 17, 2022
by Sisu Pharma News Release

Study Reveals Stress Response Protein’s Critical Role in Leukemia Stem Cell Renewal

A study identified Heat Shock Transcription Factor 1 (HSF1) as a key protein driving the renewal of leukemia stem cells in Acute Myeloid Leukemia (AML). The work is featured in Nature Communications Cancer Highlights.

Read More
Prostate Cancer
December 16, 2020
by Sisu Pharma News Release

Breakthrough Study Shows Potential New Treatment for Therapy-Resistant Prostate Cancer

A new study published in the journal Science Translational Medicine has revealed a potential breakthrough in the treatment of therapy-resistant prostate cancer.

Read More

Search

Find Us

Address
123 Main Street
New York, NY 10001

Hours
Monday–Friday: 9:00AM–5:00PM
Saturday & Sunday: 11:00AM–3:00PM

Calendar

May 2023
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
« Apr    

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
cropped-Untitled_design__1_-removebg-preview.png

Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.

Useful Links
  • Home
  • Science
  • News
© 2023 . All rights reserved. Powered by Phlox Theme Privacy Policy
Shopping Basket